Track topics on Twitter Track topics that are important to you
Patients with advanced papillary renal cell carcinoma harbouring MET alterations could respond to treatment with the selective MET tyrosine kinase inhibitor savolitinib, according to the results of a recent clinical trial.
Original Article: [News] Savolitinib for -driven papillary renal cell carcinomaNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...